01-02-2021 | Hepatocellular Carcinoma | Original Article
The introduction of immunosuppressor (TDO inhibitor) significantly improved the efficacy of irinotecan in treating hepatocellular carcinoma
Published in: Cancer Immunology, Immunotherapy | Issue 2/2021
Login to get access